Sharekhan's research report on Abbott India
Abbott India Limited (Abbott) reported strong performance in Q2FY23, with revenue and PAT growing by 13% and 38% y-o-y, respectively, while EBITDA margin expanded by 364 bps y-o-y to 24.9%. The company delivered strong operating performance in Q2FY2023 as major operating costs declined on y-o-y basis, leading to improvement in the EBITDA margin, despite a 108 bps y-o-y decline in the gross margin. Employee/other expenses were lower by 4.7%/11.7% y-o-y, respectively. Revenues and earnings are expected to clock a strong 12% and 16% CAGR over FY2022-FY2025E led by healthy growth prospects, a strong debt-free balance sheet and strong brand equity built over the years.
Outlook
We maintain a Buy on the stock with an unchanged PT of Rs. 22,780. The stock currently trades at 44.9x/38.7x its FY2023E/FY2024E EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.